14,504 Zoetis Inc. $ZTS Shares Sold by MGO One Seven LLC

Key Points

• MGO One Seven LLC cut its Zoetis stake by 63.5%, selling 14,504 shares in the third quarter and retaining 8,351 shares valued at about $583,000.
• Institutional investors own 92.8% of Zoetis shares, with several major firms adding to their positions. Analysts’ consensus rating is Hold, with a $101.25 average price target.
• Zoetis beat quarterly earnings and revenue estimates and raised its full-year profit outlook, but revenue fell 1.3% year over year. Weakness in companion-animal demand, competitive pressure, and a cautious outlook remain concerns.

MGO One Seven LLC trimmed its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 63.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 8,351 shares of the company's stock after selling 14,504 shares during the quarter. MGO One Seven LLC's holdings in Zoetis were worth $583,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the stock. BlackRock Inc. grew its position in Zoetis by 10.8% in the second quarter. BlackRock Inc. now owns 39,430,181 shares of the company's stock valued at $2,833,453,000 after acquiring an additional 3,845,869 shares during the period. State Street Corp raised its stake in Zoetis by 1.8% during the second quarter. State Street Corp now owns 19,667,723 shares of the company's stock worth $1,413,323,000 after acquiring an additional 343,322 shares in the last quarter. Deutsche Bank AG lifted its holdings in shares of Zoetis by 5.8% during the second quarter. Deutsche Bank AG now owns 5,851,737 shares of the company's stock valued at $420,506,000 after acquiring an additional 319,709 shares during the period. Bank of America Corp DE lifted its holdings in shares of Zoetis by 7.3% during the first quarter. Bank of America Corp DE now owns 4,831,652 shares of the company's stock valued at $571,150,000 after acquiring an additional 327,313 shares during the period. Finally, Van ECK Associates Corp boosted its stake in shares of Zoetis by 7.7% in the 2nd quarter. Van ECK Associates Corp now owns 4,252,140 shares of the company's stock valued at $305,559,000 after purchasing an additional 303,395 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Zacks Research raised shares of Zoetis from a "strong sell" rating to a "hold" rating in a report on Monday, October 26th. Weiss Ratings raised shares of Zoetis from a "sell (d)" rating to a "sell (d+)" rating in a report on Thursday, October 29th. UBS Group lifted their price target on shares of Zoetis from $80.00 to $85.00 and gave the company a "neutral" rating in a report on Tuesday, October 27th. JPMorgan Chase & Co. reduced their price target on shares of Zoetis from $130.00 to $115.00 and set an "overweight" rating on the stock in a research report on Friday, August 7th. Finally, Piper Sandler decreased their price objective on shares of Zoetis from $90.00 to $80.00 and set a "neutral" rating on the stock in a research note on Monday, August 10th. Eight analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Zoetis has a consensus rating of "Hold" and a consensus target price of $101.25.

Zoetis Price Performance

Shares of ZTS stock opened at $79.50 on Friday. The stock has a 50-day moving average price of $75.68 and a 200 day moving average price of $92.60. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87. The firm has a market cap of $32.85 billion, a price-to-earnings ratio of 13.52, a PEG ratio of 1.17 and a beta of 0.67. Zoetis Inc. has a 12 month low of $68.77 and a 12 month high of $132.49.

Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Thursday, November 5th. The company reported $1.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.51 by $0.24. The company had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 26.15% and a return on equity of 86.34%. The company's revenue was down 1.3% compared to the same quarter last year. During the same period in the prior year, the company posted $1.70 EPS. Research analysts expect that Zoetis Inc. will post 6.25 EPS for the current year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, October 30th will be paid a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Friday, October 30th. Zoetis's payout ratio is 34.93%.

Key Stories Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Adjusted EPS of $1.75 topped the $1.51 consensus, while revenue of $2.39 billion exceeded expectations of $2.30 billion. Zoetis also raised its full-year 2026 profit outlook. Zoetis Lifts Annual Outlook While Braces For Cautious Pet Economy
• Positive Sentiment: Livestock revenue grew 7% to $797 million, helping offset softness in companion-animal products. Jefferies also raised its price target to $85 from $83. Zoetis: 3 Key Takeaways for Long-Term Investors
• Negative Sentiment: Investors appear focused on ongoing pressure in the pet-health business: owners are cutting back on veterinary visits, and Zoetis is taking a cautious view of 2027. Competitive pressures and margin headwinds also weigh on the outlook. Zoetis plans cautiously for 2027 as pet owners cut back on vet visits, shares fall ZTS Q3 2026 deep dive: Competitive pressures and margin headwinds weigh on outlook
• Negative Sentiment: Despite beating estimates, quarterly revenue declined 1.3% year over year, reinforcing concerns that strength in livestock may not fully offset weaker companion-animal demand. Zoetis reports third-quarter results

Zoetis Company Profile

Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish.

The company's offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.

Zoetis originated as Pfizer's animal health business and became an independent public company in 2013.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.